192 related articles for article (PubMed ID: 30606407)
1. Dysregulated Mineral Metabolism in AKI.
Leaf DE; Christov M
Semin Nephrol; 2019 Jan; 39(1):41-56. PubMed ID: 30606407
[TBL] [Abstract][Full Text] [Related]
2. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP
Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor 23 and Klotho in AKI.
Christov M; Neyra JA; Gupta S; Leaf DE
Semin Nephrol; 2019 Jan; 39(1):57-75. PubMed ID: 30606408
[TBL] [Abstract][Full Text] [Related]
5. Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study.
Zehnder D; Landray MJ; Wheeler DC; Fraser W; Blackwell L; Nuttall S; Hughes SV; Townend J; Ferro C; Baigent C; Hewison M
Nephron Clin Pract; 2007; 107(3):c109-16. PubMed ID: 17890873
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery.
Leaf DE; Christov M; Jüppner H; Siew E; Ikizler TA; Bian A; Chen G; Sabbisetti VS; Bonventre JV; Cai X; Wolf M; Waikar SS
Kidney Int; 2016 Apr; 89(4):939-48. PubMed ID: 26924052
[TBL] [Abstract][Full Text] [Related]
7. Serum sclerostin in acute kidney injury patients.
Fayed A; Abdulazim DO; Amin M; Elhadidy S; Samir HH; Salem MM; Abd ElAzim IM; El Hawary KES; Sharaf El Din UA;
Nefrologia (Engl Ed); 2022; 42(1):50-55. PubMed ID: 36153899
[TBL] [Abstract][Full Text] [Related]
8. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients.
Leaf DE; Siew ED; Eisenga MF; Singh K; Mc Causland FR; Srivastava A; Alp Ikizler T; Ware LB; Ginde AA; Kellum JA; Palevsky PM; Wolf M; Waikar SS
Clin J Am Soc Nephrol; 2018 Apr; 13(4):531-541. PubMed ID: 29519954
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D, parathyroid hormone, and bone mineral density status in kidney transplant recipients.
Savaj S; Ghods FJ
Iran J Kidney Dis; 2012 Jul; 6(4):295-9. PubMed ID: 22797100
[TBL] [Abstract][Full Text] [Related]
11. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.
Hasegawa H; Nagano N; Urakawa I; Yamazaki Y; Iijima K; Fujita T; Yamashita T; Fukumoto S; Shimada T
Kidney Int; 2010 Nov; 78(10):975-80. PubMed ID: 20844473
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients.
Ramos AM; Albalate M; Vázquez S; Caramelo C; Egido J; Ortiz A
Kidney Int Suppl; 2008 Dec; (111):S88-93. PubMed ID: 19034335
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
Gutiérrez OM
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
[TBL] [Abstract][Full Text] [Related]
14. Plasma FGF23 levels increase rapidly after acute kidney injury.
Christov M; Waikar SS; Pereira RC; Havasi A; Leaf DE; Goltzman D; Pajevic PD; Wolf M; Jüppner H
Kidney Int; 2013 Oct; 84(4):776-85. PubMed ID: 23657144
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D levels in critically ill patients with acute kidney injury: a protocol for a prospective cohort study (VID-AKI).
Cameron LK; Lei K; Smith S; Doyle NL; Doyle JF; Flynn K; Purchase N; Smith J; Chan K; Kamara F; Kidane NG; Forni LG; Harrington D; Hampson G; Ostermann M
BMJ Open; 2017 Jul; 7(7):e016486. PubMed ID: 28706103
[TBL] [Abstract][Full Text] [Related]
16. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.
Sprague SM; Crawford PW; Melnick JZ; Strugnell SA; Ali S; Mangoo-Karim R; Lee S; Petkovich PM; Bishop CW
Am J Nephrol; 2016; 44(4):316-325. PubMed ID: 27676085
[TBL] [Abstract][Full Text] [Related]
17. Comparison of mineral metabolites as risk factors for adverse clinical outcomes in CKD.
Isakova T
Semin Nephrol; 2013 Mar; 33(2):106-17. PubMed ID: 23465498
[TBL] [Abstract][Full Text] [Related]
18. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE
J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657
[TBL] [Abstract][Full Text] [Related]
19. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
20. Mineral bone disorders and kidney disease in hospitalized children with sickle cell anemia.
Batte A; Kasirye P; Baluku R; Kiguli S; Kalyesubula R; John CC; Schwaderer AL; Imel EA; Conroy AL
Front Pediatr; 2022; 10():1078853. PubMed ID: 36819194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
